Research Article
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
Table 5
Overall survival according to treatment for glioblastoma and age at diagnosis.
| Treatment received | < 65 years of age at diagnosis | ≥ 65 years of age at diagnosis | P-value1 | n | Overall survival (months) | n | Overall survival (months) |
| Standard radiotherapy with concomitant and adjuvant temozolomide | 38 | 18.9 (13.7-29.4) | 15 | 16.4 (10.0-19.1) | 0.14 | Other treatment including temozolomide | 32 | 12.5 (8.1-19.6) | 45 | 6.5 (3.9-13.0) | 0.0036 | Other non-temozolomide treatment | 55 | 10.2 (5.4-13.8) | 76 | 5.5 (2.1-8.6) | 0.0013 | No treatment | 12 | 1.9 (1.0-4.1) | 34 | 1.5 (0.6-3.5) | 0.40 |
|
|
Wilcoxon rank sum test used for comparing overall survival between the two age groups. |